Abciximab is a medicine that works by inhibiting the binding of blood cells responsible for the clotting process ( platelets ).
Mechanism of action
Inhibits platelet aggregation. Platelet surface GPIIb / IIIa receptor antagonist.
Classification =
Glycoprotein inhibitors iib / iia.
Therapeutic indications
Associated with heparin and ASA in:
- Prevention of ischemic heart complications in patients undergoing percutaneous coronary intervention ( balloon angioplasty , atherectomy, and stent placement ).
Short-term reduction (1 month) in the risk of myocardial infarction in patients with unstable angina without response to conventional treatment, scheduled for percutaneous coronary intervention .
Dose
The bolus injection dose will be based on your body weight. The dose is 0.25 milligrams for every kilogram of your body weight. The infusion dose will also be based on your body weight. The dose is 0.125 micrograms per kilogram per minute , up to a maximum of 10 micrograms per minute.
Contraindications
Hypersensitivity to abciximab or to murine monoclonal antibodies ; internal bleeding; history of stroke in the previous 2 years; trauma , intra-spinal , intracranial, or major surgery in the previous 2 months; intracranial neoplasia ; aneurysm or arteriovenous malformation ; hemorrhagic diathesis ; Severe uncontrolled hypertension; thrombocytopenia ; vasculitis ; diabetic or hypertensive retinopathy ; Severe IH; patients with severe kidney failure requiring hemodialysis .
Warnings and cautions
Risk of bleeding . Monitor coagulation, electrocardiogram and vital signs . The transfusion of platelets restore platelet function. Caution if other drugs that affect hemostasis are administered . Thrombocytopenia risk ; monitor platelets. Possible hypersensitivity in case of re-administration. Decreases the effect on kidney disease. Children and over 80 years (there are no studies).
- Liver failure
Contraindicated in severe HI.
- Renal insufficiency
Contraindicated in patients with severe renal failure requiring hemodialysis. It should be administered with special caution in case of suffering from any of the following diseases: active stomach ulcer , kidney disease or clotting problems . During the administration of abciximab an allergic reaction can occur at any time. A blood test should be done before this drug is given to monitor the number of platelets in the patient’s blood .
Affects other medications
Tell your doctor if you have taken medications that thin the blood, or any other medications that affect blood clotting (anticoagulants) or blood platelets (antiplatelet medications). It is especially important to tell your doctor if you have been given thrombolytic drugs to unblock your arteries. Co-administration of abciximab with these drugs may increase the risk of bleeding. Inform your doctor or pharmacist of any medications you are taking.
Adverse reactions
Thrombocytopenia ; bradycardia ; nausea , vomiting ; chest pain , fever , pain at the puncture site , abdominal pain ; lumbar pain ; headache ; bleeding , hypotension , peripheral edema .